High-Concentration CXCR5 Antibody Formulations for Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical formulations containing high concentrations of anti-CXCR5 binding agents face issues such as increased viscosity, pH shift, solution color change, formation of particles and aggregates, and interaction with storage containers, necessitating improved formulations for extended stability.
Innovation Solution
Anti-CXCR5 antibody formulations with specific compositions including citrate buffer, surfactant, amino acid, and sucrose, optimized for subcutaneous administration, which enhance storage stability in glass containers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high concentration (20-250 mg/mL) anti-CXCR5 antibody formulations are used, then therapeutic efficacy is improved, but viscosity increases and stability decreases
Solution Approach 1:
The patent optimizes multiple formulation parameters including pH (adjusted to specific ranges), ionic strength, and excipient concentrations to stabilize high-concentration antibody formulations. By systematically adjusting these parameters, the formulation maintains stability at therapeutic concentrations of 20-250 mg/mL while preventing aggregation and degradation.
Solution Approach 2:
The patent introduces excipients as intermediary substances that mediate between the high-concentration antibody and the formulation environment. These excipients act as protective intermediaries that prevent direct harmful interactions, reduce aggregation, and maintain solubility and stability at high antibody concentrations.
2Quantity of substance
If high concentration (20-250 mg/mL) anti-CXCR5 antibody formulations are used, then therapeutic efficacy is improved, but particle formation increases
Solution Approach 1:
Surfactants are introduced as intermediary substances that adsorb at interfaces and prevent protein-protein interactions that lead to aggregation. These surfactant intermediaries reduce surface tension and prevent the formation of visible and sub-visible particles at high antibody concentrations.
Solution Approach 2:
The patent adjusts formulation parameters such as pH, ionic strength, and excipient concentrations to optimize solubility and minimize aggregation. By controlling these parameters within specific ranges, the formulation maintains high antibody concentration while suppressing particle formation through altered protein-solution interactions.
3Quantity of substance
If high concentration (20-250 mg/mL) anti-CXCR5 antibody formulations are used, then therapeutic efficacy is improved, but interaction with storage container increases
Solution Approach 1:
The formulation includes excipients that act as intermediaries between the high-concentration antibody solution and the glass storage container. These intermediary substances reduce direct contact and interaction between the antibody and container surface, preventing adsorption, denaturation, or other container-related degradation mechanisms.
Solution Approach 2:
The patent optimizes formulation parameters including pH, ionic strength, and surfactant concentration to minimize electrostatic and hydrophobic interactions between the antibody and glass container surface. By adjusting these parameters, the formulation reduces container interaction while maintaining high therapeutic concentration.
4Quantity of substance
If high concentration (20-250 mg/mL) anti-CXCR5 antibody formulations are used, then therapeutic efficacy is improved, but pH stability decreases
Solution Approach 1:
The patent employs optimized buffering systems with specific pH ranges to counteract pH shifts that occur at high antibody concentrations. By adjusting buffer capacity, pH, and ionic strength, the formulation maintains pH stability despite the high concentration of antibody that would otherwise cause significant pH drift.
Data Source
AI summary
High concentration antibody formulations capable of stable long-term storage are disclosed.